QDOLO (tramadol hydrochloride) by Athena Bioscience is tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin re- uptake. First approved in 2020.
Drug data last refreshed 21h ago · AI intelligence enriched 5d ago
QDOLO is an oral solution formulation of tramadol hydrochloride, a centrally acting analgesic approved in 2020. It works through dual mechanisms: μ-opioid receptor agonism and inhibition of norepinephrine and serotonin reuptake, with analgesic onset within one hour and peak effect at 2–3 hours. The active metabolite M1 is significantly more potent than the parent compound, contributing substantially to analgesia in humans.
QDOLO is in peak lifecycle phase with 14 years of patent protection remaining, suggesting stable commercial operations and moderate team size focused on maintenance and optimization.
tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin re- uptake. Although the mode of action is not completely understood, the analgesic effect of tramadol is believed to be due to both binding to μ-opioid receptors and weak inhibition of re-uptake of norepinephrine and…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain
Bioequivalence Study of Tramadol Hydrochloride /Paracetamol Tablets Versus Ultracet Tablets
Tramadol Hydrochloride and Dexketoprofen Trometamol for the Oral Treatment of Moderate to Severe Acute Pain Following Removal of Impacted Lower Third Molar
Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants
A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers
Worked on QDOLO at Athena Bioscience? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moCareer opportunities on QDOLO are highly specialized, with only one linked position currently reported in a Collections/Risk focus area, suggesting a limited team or niche operational need. This indicates a smaller portfolio or post-launch commercial operation rather than a high-growth launch environment.
1 open roles linked to this drug